Can a GLP-1 improve menstrual regularity in women with PCOS?

# Can a GLP-1 improve menstrual regularity in women with PCOS?

If your periods with PCOS are unpredictable, skipped, or missing for months at a time, you are not imagining how disruptive that is. Cycles are a signal from the body, and when they go quiet it can feel like something is broken. A common question now is whether the newer weight and metabolic medicines might help those cycles settle into a more regular rhythm. The honest answer is that there is a real and growing signal here, mostly working through weight and insulin resistance, but the evidence is still early. Here is what the research actually shows, so you can bring sharper questions to your clinician.

Key takeaways

Dr. Linda's take

Women come in asking a very specific version of this question: not "will I lose weight," but "will my period come back." That is a different question, and it deserves a careful answer rather than a hopeful one.

Here is how I hold it. Polycystic ovary syndrome is a heterogeneous disorder characterized by hyperandrogenism and chronic anovulation. Chronic anovulation is the clinical way of saying that ovulation becomes irregular or stops, which is why cycles scatter or disappear. Underneath a lot of that sits metabolism. Insulin resistance is present in a majority of cases, with compensatory hyperinsulinemia contributing to hyperandrogenism via stimulation of ovarian androgen secretion and inhibition of hepatic sex hormone binding globulin production. So when a medicine improves weight and insulin sensitivity, it is reasonable to hope some of that pressure on the cycle eases too.

What I will not do is promise you a regular period from a prescription. The research points in an encouraging direction, but it is early, and cycles are personal. If you want a starting point for whether any of this fits your situation, our eligibility quiz is a reasonable first step. It is a starting point, not a plan.

Why are periods irregular in PCOS?

Start with the mechanism, because it explains everything that follows. Polycystic ovary syndrome is a heterogeneous disorder characterized by hyperandrogenism and chronic anovulation. When ovulation does not happen on a regular schedule, the lining of the uterus is not shed on a regular schedule either, and that is what shows up as long, unpredictable, or missing cycles.

Metabolism is woven through this. Insulin resistance is present in a majority of cases, with compensatory hyperinsulinemia contributing to hyperandrogenism via stimulation of ovarian androgen secretion and inhibition of hepatic sex hormone binding globulin production. In plainer terms, when the body has to pump out extra insulin, that extra insulin can nudge the ovaries toward making more androgens, and higher androgens are part of what keeps ovulation from happening on time. This is why so much of PCOS care aims at the metabolic engine, not just the symptom.

How could a GLP-1 make cycles more regular?

The logic runs through weight and insulin resistance, not through a direct hormonal switch. Weight loss is regarded as the first-line treatment for PCOS because it can improve androgen levels, menstrual cyclicity, and glucose metabolism. If a medicine helps with that first-line goal, the hope is that cycle regularity follows.

The older comparison here is metformin, a pill used for decades in PCOS. In non-pregnant women, metformin improves insulin resistance, menstrual regularity, and androgen levels, particularly in those with obesity or insulin resistance. That tells you the pathway is real: move insulin resistance, and periods can move with it.

The newer medicines are being studied along the same pathway. GLP-1 receptor agonists have been used as monotherapy or in combination with metformin to manage obesity and insulin resistance associated with PCOS. And the metabolic effect is measurable. In a 2025 meta-analysis, GLP-1 receptor agonists significantly reduced fasting insulin, glucose level at 2 hours after an oral glucose tolerance test, and HOMA-IR, a common marker of insulin resistance. In a 2026 systematic review and meta-analysis of eighteen randomized trials, insulin resistance improved significantly with GLP-1 receptor agonists, particularly with exenatide. So the first two dominoes, weight and insulin sensitivity, do appear to move.

What does the research actually show on periods?

This is the part people most want, and it is genuinely encouraging, with an important asterisk.

In a 2025 systematic review and network meta-analysis of twenty-seven randomized trials, GLP-1 receptor agonists, alone and in combination with metformin, were observed to improve menstrual frequencies. That is the clearest direct statement in the literature that these medicines are associated with more regular cycles, not just lower weight. However, the reviewers cautioned that the strength of evidence for these findings was very low. Both halves of that sentence matter: a real signal, and a caution about how firmly we can lean on it.

Other reviews echo the direction. In an earlier review of GLP-1 in reproduction, preliminary data from interventional clinical studies suggested improved menstrual regularity in overweight or obese women with PCOS. A separate narrative review reported significant weight loss and testosterone reduction with GLP-1 receptor agonists in women with obesity and PCOS, with mixed results relative to improvements in insulin resistance parameters and menstrual patterns. That word "mixed" is the honest one. Not every study lands in the same place.

There is also a specific trial worth naming. In a 16-week randomized trial in overweight and obese women with PCOS, the group taking semaglutide plus metformin showed higher rates of menstrual cycle recovery than the group taking metformin alone. It is one small, short study, but it points the same way as the reviews.

How strong is this evidence, really?

Strong enough to take seriously, not strong enough to treat as settled. Because these studies are mostly small and short, the long-term effects of GLP-1 receptor agonist use in PCOS remain undetermined. Across this body of work, researchers note that the low certainty of much of the evidence underscores the need for large, long-term randomized trials to confirm these findings.

It is also worth remembering that these medicines carry side effects. In that 2025 analysis, GLP-1 receptor agonists increased nausea, vomiting and dizziness. None of this rules the option in or out for you. It is context for a conversation, not a verdict. You can read more about the mechanism in how these medicines affect insulin resistance in PCOS and how the options compare in metformin versus these medicines for PCOS.

What should you ask your clinician?

A few questions tend to make these visits more useful. Ask whether your particular pattern of irregular cycles is being driven more by weight, by insulin resistance, by androgens, or by some combination, because the answer shapes the plan. Ask what a realistic timeline looks like, since cycle changes tend to follow metabolic changes rather than appear overnight. Ask about side effects you are willing to live with. And if pregnancy is part of your picture, the timing of these medicines around conception is a separate conversation, and we walk through it in do you need to stop these medicines before trying to get pregnant with PCOS. You can also read about how these medicines affect androgens in how this medication class shifts testosterone in women with PCOS.

Frequently asked questions

Will a GLP-1 bring my period back?

It might help, but no one can promise it. In a 2025 systematic review and network meta-analysis of twenty-seven randomized trials, GLP-1 receptor agonists, alone and in combination with metformin, were observed to improve menstrual frequencies. However, the reviewers cautioned that the strength of evidence for these findings was very low. The effect appears to travel with weight and insulin sensitivity, so results differ from person to person.

Is it the medicine or the weight loss that helps periods?

Most of the current thinking points to the metabolic pathway. Weight loss is regarded as the first-line treatment for PCOS because it can improve androgen levels, menstrual cyclicity, and glucose metabolism. In a 2025 meta-analysis, GLP-1 receptor agonists significantly reduced fasting insulin, glucose level at 2 hours after an oral glucose tolerance test, and HOMA-IR, a common marker of insulin resistance. The cycle changes seem to follow those shifts rather than come from a direct hormonal switch.

How does this compare with metformin for periods?

Both work along the same pathway. In non-pregnant women, metformin improves insulin resistance, menstrual regularity, and androgen levels, particularly in those with obesity or insulin resistance. We compare the two options more fully in metformin versus these medicines for PCOS.

Is this a fertility treatment?

No. These medicines are studied for weight, insulin resistance, and related markers, not as fertility drugs, and questions about trying to conceive have their own timing and safety considerations. If that is where you are headed, start with do you need to stop these medicines before trying to get pregnant with PCOS and a clinician who knows your history.

Is the evidence solid yet?

Not fully. Because these studies are mostly small and short, the long-term effects of GLP-1 receptor agonist use in PCOS remain undetermined. Across this body of work, researchers note that the low certainty of much of the evidence underscores the need for large, long-term randomized trials to confirm these findings.

References

1. Human reproduction update (2019). The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective. PubMed PMID 31260047. https://pubmed.ncbi.nlm.nih.gov/31260047/ (Accessed 2026-07-25).
2. The Journal of clinical endocrinology and metabolism (2020). Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists. PubMed PMID 32442310. https://pubmed.ncbi.nlm.nih.gov/32442310/ (Accessed 2026-07-25).
3. Journal of ovarian research / Fertility and Sterility literature (2021). Polycystic ovary syndrome and insulin resistance. PubMed PMID 21263450. https://pubmed.ncbi.nlm.nih.gov/21263450/ (Accessed 2026-07-25).
4. Reproductive health / PCOS management review (2019). Polycystic ovary syndrome interventions. PubMed PMID 31384717. https://pubmed.ncbi.nlm.nih.gov/31384717/ (Accessed 2026-07-25).
5. Women's health (London, England) (2024). A systematic review of GLP-1 on anthropometrics, metabolic and endocrine parameters in patients with PCOS. PubMed PMID 38444070. https://pubmed.ncbi.nlm.nih.gov/38444070/ (Accessed 2026-07-25).
6. Diabetes, obesity & metabolism (2025). Metformin use in women with polycystic ovary syndrome (PCOS): Opportunities, benefits, and clinical challenges. PubMed PMID 40329601. https://pubmed.ncbi.nlm.nih.gov/40329601/ (Accessed 2026-07-25).
7. Diabetology & metabolic syndrome (2025). Expanding therapeutic horizons: GLP-1 receptor agonists and SGLT-2 inhibitors in polycystic ovarian syndrome: a systematic review and network meta-analysis of randomized clinical trials. PubMed PMID 40410888. https://pubmed.ncbi.nlm.nih.gov/40410888/ (Accessed 2026-07-25).
8. Systematic review and meta-analysis of GLP-1 receptor agonists in PCOS (2025). GLP-1 receptor agonists and glucose homeostasis in PCOS. PubMed PMID 40360648. https://pubmed.ncbi.nlm.nih.gov/40360648/ (Accessed 2026-07-25).
9. Systematic review and meta-analysis of GLP-1 receptor agonists in PCOS (2026). Insulin resistance outcomes with GLP-1 receptor agonists in PCOS. PubMed PMID 42116999. https://pubmed.ncbi.nlm.nih.gov/42116999/ (Accessed 2026-07-25).
10. Reproductive biology and endocrinology : RB&E (2025). Effects of combined metformin and semaglutide therapy on body weight, metabolic parameters, and reproductive outcomes in overweight/obese women with polycystic ovary syndrome: a prospective, randomized, controlled, open-label clinical trial. PubMed PMID 40713699. https://pubmed.ncbi.nlm.nih.gov/40713699/ (Accessed 2026-07-25).
11. Cureus (2024). GLP-1 receptor agonists for weight loss in women with polycystic ovary syndrome: a scoping review. PubMed PMID 39262529. https://pubmed.ncbi.nlm.nih.gov/39262529/ (Accessed 2026-07-25).
12. Network meta-analysis of antidiabetic and metabolic drugs in PCOS (2026). Comparative effects on hyperandrogenism and metabolic outcomes. PubMed PMID 41862977. https://pubmed.ncbi.nlm.nih.gov/41862977/ (Accessed 2026-07-25).

---

*This article is general education and is not medical advice. It cannot tell you what is right for your body. Talk with a licensed clinician about your own situation.*

*Written and clinically reviewed by Dr. Linda Moleon, MD. Last reviewed 2026-07-25.*